Navigation Links
Internal Fixation Systems Announces 510(k) Approval Granted by FDA for Subtalar Implants
Date:1/23/2012

MIAMI, Jan. 23, 2012 /PRNewswire/ -- (OTC: IFIX) Internal Fixation Systems today announced that it has received 510(k) clearance from the FDA to market subtalar implants. These implants are used to preserve motion at the ankle joint and to treat both trauma conditions and arthritis.  IFS CEO, Stephen Dresnick, MD, stated that, "this approval allows us to continue to fill out our portfolio, and gives us another product for surgeons who use our products." IFS currently offers a full line of mini-cannulated screws for small bone fixation as well as a Modular Locking Small Fragment System for treatment of bone fractures and osteotomies. 

About IFS:  Internal Fixation Systems, Inc is a manufacturer and marketer of high quality, responsibly priced orthopedic and podiatric implants.
We seek to prove that superior products and lower costs can go hand in hand.   IFS focuses on widely used, market proven products used to treat common fractures.  Our Advisory Panel, consisting of nationally recognized surgeons, provides input on how to improve our implant designs.  The resulting products incorporate doctor requested enhancements and are priced at 40-60% less than the competition.  IFS customers include ambulatory surgery centers, hospitals and orthopedic surgeons.  Please contact us for more information about our product and business model.
This press release contains projections and forward-looking information that involve various risks and uncertainties regarding future events.  Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of Internal Fixation, such as whether we sell our new product offering  There are numerous risks and uncertainties that could cause actual results and Internal Fixation's plans and objectives to differ materially from those expressed in the forward-looking information, including whether Internal Fixation will have sufficient capital to continue its operations..  Actual results and future events could differ materially from those anticipated in such information.  These and all subsequent written and oral forward-looking information are based on estimates and views of  management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, IFS does not intend to update these forward-looking statements.For further information, please contact:

Laura Cattabriga, Chief Financial Officer

  

Tel: 786 268 0995

  

Laura.cattabriga@ifsusa.net

 


'/>"/>

SOURCE Internal Fixation Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. JCM Passes Internal Quality Assessment for Azithromycin API Production
2. Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers
3. Internal Fixation Systems, Inc. Announces Sale of Modular Locking Small Fragment System
4. Internal Fixation Systems, Inc. Announces DTC Eligibility
5. Internal Fixation Systems, Inc. Receives FDA 510(k) Clearance to Market Fixation Devices to Treat Bone Fractures and Osteotomies
6. Internal Groups are Valuable Sources for Pharmaceutical Competitive Intelligence Function
7. Building Support for a New Product Through Effective Internal Disease State Communication
8. Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities
9. Internal Fixation Systems, Inc. Announces Form S-1 Declared Effective by SEC and Anticipated Quotation for Trading on OTCQB
10. Maximizing the Potential of Internal and External Communications Groups
11. Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):